Tekmira Expands Bristol Deal

Xconomy Seattle — 

Tekmira Pharmaceuticals, the Vancouver, BC-based developer of technology to RNA interference drugs, said today it has signed a four-year collaboration with Bristol-Myers Squibb. Bristol will pay Tekmira $3 million upfront, while Tekmira will be asked to deliver a pre-determined number of batches of RNAi drug candidates in lipid nanoparticles.  Tekmira has other collaborations with Pfizer, Roche, and Alnylam Pharmaceuticals.